Table 2.

Change from baseline to endpoint (52 weeks) on individual efficacy scales in early-stage subjects.

Variable	Aripiprazole (N = 100)		Haloperidol (N = 32)		P-value
	*LS Mean	SE	LS Mean	SE
PANSS total	−44.42	1.03	−39.92	1.58	0.017
PANSS negative	−10.01	0.3	−8.68	0.46	0.016
PANSS positive	−14.17	0.3	−14.00	0.47	0.759
PANSS general	−20.29	0.53	−17.35	0.81	0.002
CGI severity	−2.19	0.06	−1.99	0.09	0.07
MADRS total	−5.78	0.51	−3.74	0.65	0.001

^*Mixed model, observed cases; LS, least square.